{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:44:54Z","timestamp":1789523094553,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.medj.2024.05.018","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:32:26Z","timestamp":1719225146000},"page":"1178-1189.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study"],"prefix":"10.1016","volume":"5","author":[{"given":"Alan K.","family":"Percy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Neul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Benke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Berry-Kravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Glaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathie M.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.05.018_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.medj.2024.05.018_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fncel.2014.00018","article-title":"Developmental and maintenance defects in Rett syndrome neurons identified by a new mouse staging system in\u00a0vitro","volume":"8","author":"Baj","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.medj.2024.05.018_bib3","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/cercor\/bhv078","article-title":"Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms","volume":"26","author":"Bedogni","year":"2016","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.medj.2024.05.018_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cne.22009","article-title":"Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks","volume":"514","author":"Belichenko","year":"2009","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.medj.2024.05.018_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","article-title":"Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome","volume":"55","author":"Motil","year":"2012","journal-title":"J.\u00a0Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.medj.2024.05.018_bib6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ana.22124","article-title":"Rett syndrome: revised diagnostic criteria and nomenclature","volume":"68","author":"Neul","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.medj.2024.05.018_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mrdd.10020","article-title":"Clinical manifestations and stages of Rett syndrome","volume":"8","author":"Hagberg","year":"2002","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"key":"10.1016\/j.medj.2024.05.018_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ajmg.1320250506","article-title":"Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence","volume":"1","author":"Hagberg","year":"1986","journal-title":"Am. J. Med. Genet. Suppl."},{"key":"10.1016\/j.medj.2024.05.018_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pediatrneurol.2015.12.021","article-title":"Caretaker quality of life in Rett syndrome: disorder features and psychological predictors","volume":"58","author":"Killian","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.medj.2024.05.018_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12883-023-03181-y","article-title":"Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study","volume":"23","author":"May","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.medj.2024.05.018_bib11","series-title":"DAYBUE (Trofinetide) [package insert] (San Diego, CA)","year":"2023"},{"key":"10.1016\/j.medj.2024.05.018_bib12","doi-asserted-by":"crossref","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.05.018_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","article-title":"A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome","volume":"76","author":"Glaze","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.medj.2024.05.018_bib14","first-page":"e304","article-title":"Efficacy and safety of trofinetide for the treatment of Rett syndrome: results from the pivotal phase 3 LAVENDER study","volume":"99","author":"Neul","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.05.018_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21678707.2023.2217328","article-title":"Recommendations for the management of diarrhea with trofinetide use in Rett syndrome","volume":"11","author":"Marsh","year":"2023","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.medj.2024.05.018_bib16","doi-asserted-by":"crossref","first-page":"e000717","DOI":"10.1136\/bmjpo-2020-000717","article-title":"Consensus guidelines on managing Rett syndrome across the lifespan","volume":"4","author":"Fu","year":"2020","journal-title":"BMJ Paediatr. Open"},{"key":"10.1016\/j.medj.2024.05.018_bib17","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1177\/0883073815579707","article-title":"Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the Clinical Global Impression Scale","volume":"30","author":"Neul","year":"2015","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.medj.2024.05.018_bib18","doi-asserted-by":"crossref","first-page":"e2594","DOI":"10.1212\/WNL.0000000000007560","article-title":"Hand stereotypies: lessons from the Rett Syndrome Natural History Study","volume":"92","author":"Stallworth","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.05.018_bib19","first-page":"241","article-title":"Hy's law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.medj.2024.05.018_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MPG.0b013e31829e0b65","article-title":"Assessment and management of nutrition and growth in Rett syndrome","volume":"57","author":"Leonard","year":"2013","journal-title":"J.\u00a0Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.medj.2024.05.018_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/17518423.2013.879940","article-title":"Parental perspectives on the communication abilities of their daughters with Rett syndrome","volume":"19","author":"Urbanowicz","year":"2016","journal-title":"Dev. Neurorehabil."},{"key":"10.1016\/j.medj.2024.05.018_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.pediatrneurol.2015.02.007","article-title":"Age of diagnosis in Rett syndrome: patterns of recognition among diagnosticians and risk factors for late diagnosis","volume":"52","author":"Tarquinio","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.medj.2024.05.018_bib23","series-title":"ASCEND\/IRSF Rett Syndrome National Summit","article-title":"Design and outcome measures of an open-label study of trofinetide for the treatment of girls 2 to 5 years of age with Rett syndrome","author":"Ryther","year":"2022"},{"key":"10.1016\/j.medj.2024.05.018_bib24","series-title":"51st Child Neurology Society Annual Meeting","article-title":"An open-label study of trofinetide for the treatment of Rett syndrome in girls 2\u20134 years of age (DAFFODIL)","author":"Percy","year":"2022"},{"key":"10.1016\/j.medj.2024.05.018_bib25","series-title":"Open-label Extension Study of Trofinetide for Rett Syndrome","year":"2023"},{"key":"10.1016\/j.medj.2024.05.018_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajmg.b.32707","article-title":"The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2","volume":"180","author":"Neul","year":"2019","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.medj.2024.05.018_bib27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/1469-7610.00236","article-title":"The Rett Syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome","volume":"43","author":"Mount","year":"2002","journal-title":"J.\u00a0Child Psychol. Psychiatry"},{"key":"10.1016\/j.medj.2024.05.018_bib28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/1362361314542955","article-title":"Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder","volume":"19","author":"Anagnostou","year":"2015","journal-title":"Autism"},{"key":"10.1016\/j.medj.2024.05.018_bib29","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1044\/1092-4388(2002\/097)","article-title":"Validity and reliability of the Communication and Symbolic Behavior Scales Developmental Profile with very young children","volume":"45","author":"Wetherby","year":"2002","journal-title":"J.\u00a0Speech Lang. Hear. Res."},{"key":"10.1016\/j.medj.2024.05.018_bib30","doi-asserted-by":"crossref","first-page":"106704","DOI":"10.1016\/j.cct.2022.106704","article-title":"Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome","volume":"114","author":"Neul","year":"2022","journal-title":"Contemp. Clin. Trials"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024002228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024002228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T19:31:26Z","timestamp":1759865486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024002228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2666634024002228"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.05.018","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}